PF-Atlas › Clinical Trials › NCT07600021
A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis
SYH2059 Tablets · Phase 2
Registry ID
NCT07600021
Phase
Phase 2
Status
Not yet recruiting
Drug / intervention
SYH2059 Tablets
Sponsor
InnovStone Therapeutics Limited
Start
2026-06-30
Enrollment
156
About this trial
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT07600021 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.